Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 331

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities

Open access
Tabrizi, Sarah J, Estevez-Fraga, Carlos, van Roon-Mom, Willeke M C, Flower, Michael D, Scahill, Rachael I, Wild, Edward J, Muñoz-Sanjuan, Ignacio, Sampaio, Cristina, Rosser, Anne E, Leavitt, Blair R·2022·The Lancet Neurology

Abstract

Huntington’s disease is the most frequent autosomal dominant neurodegenerative disorder, for which we have no approved disease-modifying treatments. The molecular pathogenesis of Huntington’s disease is complex, with toxicity arising from full length expanded huntingtin and N-terminal fragments of huntingtin, which are both prone to misfolding due to proteolysis, from aberrant intron-1 splicing, and from somatic expansion of the CAG repeat in the HTT gene. Potential therapies for Huntington’s disease include those targeting huntingtin DNA and RNA, clearance of huntingtin protein, DNA repair pathways, and other treatment strategies targeting inflammation and cell replacement. The early termination of the tominersen antisense oligonucleotide trials sent a strong signal that it is timely to reflect on lessons learned, where the field stands now, and our challenges and opportunities for the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(22)00121-1

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 115 references

Cited by

See all 331

Metadata

Authors
Tabrizi, S. J., Estevez-Fraga, C., van Roon-Mom, W. M. C., Flower, M. D., Scahill, R. I., Wild, E. J., Muñoz-Sanjuan, I., Sampaio, C., Rosser, A. E., & Leavitt, B. R.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2022-07
Volume
21
Issue
7
Pages
645-658
ISSN
1474-4422 (ISSN-L)
OpenAlex
W4282972828
Cited by
331
References
115
FWCI
26.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. https://app.cochat.ai/papers/10.1016/s1474-4422(22)00121-1
The paper
Tabrizi, S. J., Estevez-Fraga, C., van Roon-Mom, W. M. C., Flower, M. D., Scahill, R. I., Wild, E. J., Muñoz-Sanjuan, I., Sampaio, C., Rosser, A. E., & Leavitt, B. R. (2022). Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(22)00121-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.